There are now many options to treated relapsed/refractory multiple myeloma (MM); however, these drugs can be costly, and access differs between countries and locations. In this interview, Jean-Luc Harousseau, MD, of the University of Nantes, Nantes, France, discusses the recommendations for and challenges of treating at relapse from a cost/efficacy point of view. Dr Harousseau discusses how this can assessed and understood, as well as how treatment duration is considered and how clinical trials can be designed to optimize this measure. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

свернуть